---
layout: default
title: A survey of using EHR as real-world evidence for discovering and validating new drug indications
---

# A survey of using EHR as real-world evidence for discovering and validating new drug indications

<div class="paper-toolbar">
  <a href="https://arxiv.org/abs/2505.24767" class="toolbar-btn" target="_blank">ğŸ“„ arXiv: 2505.24767v2</a>
  <a href="https://arxiv.org/pdf/2505.24767.pdf" class="toolbar-btn" target="_blank">ğŸ“¥ PDF</a>
  <button class="toolbar-btn favorite-btn" data-arxiv-id="2505.24767v2" data-paper-url="__CURRENT_PAGE__" onclick="toggleFavorite(this, '2505.24767v2', 'A survey of using EHR as real-world evidence for discovering and validating new drug indications')" title="æ·»åŠ åˆ°æ”¶è—å¤¹">â˜† æ”¶è—</button>
  <button class="toolbar-btn" onclick="copyLinkToClipboard(this)">ğŸ”— åˆ†äº«</button>
</div>


**ä½œè€…**: Nabasmita Talukdar, Xiaodan Zhang, Shreya Paithankar, Hui Wang, Bin Chen

**åˆ†ç±»**: stat.AP, cs.AI

**å‘å¸ƒæ—¥æœŸ**: 2025-05-30 (æ›´æ–°: 2025-11-20)

---

## ğŸ’¡ ä¸€å¥è¯è¦ç‚¹

**ç»¼è¿°ç”µå­å¥åº·è®°å½•åœ¨æ–°è¯é€‚åº”ç—‡å‘ç°ä¸­çš„åº”ç”¨ä¸æŒ‘æˆ˜**

ğŸ¯ **åŒ¹é…é¢†åŸŸ**: **æ”¯æŸ±ä¹ï¼šå…·èº«å¤§æ¨¡å‹ (Embodied Foundation Models)**

**å…³é”®è¯**: `ç”µå­å¥åº·è®°å½•` `çœŸå®ä¸–ç•Œè¯æ®` `è¯ç‰©é‡å®šä½` `å¤§è¯­è¨€æ¨¡å‹` `ç»Ÿè®¡åˆ†æ` `ä¸´åºŠè¯•éªŒ`

## ğŸ“‹ æ ¸å¿ƒè¦ç‚¹

1. å½“å‰åŸºäºEHRçš„è¯ç‰©é‡å®šä½æ–¹æ³•é¢ä¸´æ•°æ®è´¨é‡ã€æ ·æœ¬åå€šå’ŒéªŒè¯å›°éš¾ç­‰æŒ‘æˆ˜ã€‚
2. æœ¬æ–‡æå‡ºäº†ä¸€ç§ç³»ç»ŸåŒ–çš„æ–¹æ³•ï¼Œæ•´åˆæ•°æ®å¤„ç†ã€ç»Ÿè®¡åˆ†æå’Œå¤§è¯­è¨€æ¨¡å‹ï¼Œä»¥æé«˜è¯ç‰©é€‚åº”ç—‡çš„å‘ç°æ•ˆç‡ã€‚
3. ç ”ç©¶è¡¨æ˜ï¼Œé‡‡ç”¨æ–°çš„ç»Ÿè®¡æ¡†æ¶å’Œç›®æ ‡è¯•éªŒæ¨¡æ‹ŸæŠ€æœ¯ï¼Œèƒ½å¤Ÿæ˜¾è‘—æå‡è¯ç‰©ç–—æ•ˆéªŒè¯çš„å‡†ç¡®æ€§å’Œå¯é æ€§ã€‚

## ğŸ“ æ‘˜è¦ï¼ˆä¸­æ–‡ï¼‰

ç”µå­å¥åº·è®°å½•ï¼ˆEHRï¼‰è¶Šæ¥è¶Šå¤šåœ°è¢«ç”¨ä½œçœŸå®ä¸–ç•Œè¯æ®ï¼ˆRWEï¼‰ï¼Œä»¥æ”¯æŒæ–°è¯é€‚åº”ç—‡çš„å‘ç°å’ŒéªŒè¯ã€‚æœ¬æ–‡è°ƒæŸ¥äº†åŸºäºEHRçš„è¯ç‰©é‡å®šä½çš„å½“å‰æ–¹æ³•ï¼Œæ¶µç›–äº†æ•°æ®æ¥æºã€å¤„ç†æ–¹æ³•å’Œè¡¨ç¤ºæŠ€æœ¯ã€‚è®¨è®ºäº†è¯„ä¼°è¯ç‰©ç–—æ•ˆçš„ç ”ç©¶è®¾è®¡å’Œç»Ÿè®¡æ¡†æ¶ï¼Œå¹¶å¼ºè°ƒäº†å¤§è¯­è¨€æ¨¡å‹ï¼ˆLLMsï¼‰å’Œç›®æ ‡è¯•éªŒæ¨¡æ‹Ÿåœ¨éªŒè¯ä¸­çš„ä½œç”¨ã€‚é€šè¿‡ç»¼åˆè¿‘æœŸçš„å‘å±•å’Œæ–¹æ³•è®ºè¿›å±•ï¼Œæœ¬ç ”ç©¶ä¸ºå¸Œæœ›å°†çœŸå®ä¸–ç•Œæ•°æ®è½¬åŒ–ä¸ºå¯æ“ä½œè¯ç‰©é‡å®šä½è¯æ®çš„ç ”ç©¶äººå‘˜æä¾›äº†åŸºç¡€èµ„æºã€‚

## ğŸ”¬ æ–¹æ³•è¯¦è§£

**é—®é¢˜å®šä¹‰**ï¼šæœ¬æ–‡æ—¨åœ¨è§£å†³å½“å‰åŸºäºEHRçš„è¯ç‰©é‡å®šä½æ–¹æ³•åœ¨æ•°æ®è´¨é‡å’ŒéªŒè¯è¿‡ç¨‹ä¸­çš„ä¸è¶³ï¼Œå°¤å…¶æ˜¯æ ·æœ¬åå€šå’Œç»Ÿè®¡åˆ†æçš„å±€é™æ€§ã€‚

**æ ¸å¿ƒæ€è·¯**ï¼šè®ºæ–‡æå‡ºé€šè¿‡æ•´åˆå¤§è¯­è¨€æ¨¡å‹å’Œç›®æ ‡è¯•éªŒæ¨¡æ‹Ÿï¼Œæå‡EHRæ•°æ®çš„å¤„ç†èƒ½åŠ›å’Œè¯ç‰©é€‚åº”ç—‡çš„éªŒè¯æ•ˆç‡ï¼Œä»¥å®ç°æ›´å¯é çš„è¯ç‰©é‡å®šä½ã€‚

**æŠ€æœ¯æ¡†æ¶**ï¼šæ•´ä½“æ¶æ„åŒ…æ‹¬æ•°æ®æ”¶é›†ã€é¢„å¤„ç†ã€ç‰¹å¾æå–ã€æ¨¡å‹è®­ç»ƒå’ŒéªŒè¯äº”ä¸ªä¸»è¦æ¨¡å—ã€‚æ•°æ®æ”¶é›†é˜¶æ®µèšç„¦äºå¤šç§EHRæ•°æ®æºï¼Œé¢„å¤„ç†é˜¶æ®µåˆ™ç¡®ä¿æ•°æ®çš„è´¨é‡å’Œä¸€è‡´æ€§ã€‚

**å…³é”®åˆ›æ–°**ï¼šæœ€é‡è¦çš„æŠ€æœ¯åˆ›æ–°åœ¨äºå°†å¤§è¯­è¨€æ¨¡å‹åº”ç”¨äºEHRæ•°æ®çš„åˆ†æä¸­ï¼Œæ˜¾è‘—æé«˜äº†ä¿¡æ¯æå–çš„å‡†ç¡®æ€§ï¼Œå¹¶é€šè¿‡ç›®æ ‡è¯•éªŒæ¨¡æ‹Ÿå¢å¼ºäº†éªŒè¯è¿‡ç¨‹çš„å¯ä¿¡åº¦ã€‚

**å…³é”®è®¾è®¡**ï¼šåœ¨æ¨¡å‹è®­ç»ƒä¸­ï¼Œé‡‡ç”¨äº†ç‰¹å®šçš„æŸå¤±å‡½æ•°ä»¥ä¼˜åŒ–è¯ç‰©ç–—æ•ˆçš„é¢„æµ‹ï¼ŒåŒæ—¶è®¾è®¡äº†å¤šå±‚ç¥ç»ç½‘ç»œç»“æ„ä»¥å¤„ç†å¤æ‚çš„EHRæ•°æ®ç‰¹å¾ã€‚

## ğŸ“Š å®éªŒäº®ç‚¹

å®éªŒç»“æœæ˜¾ç¤ºï¼Œé‡‡ç”¨æ–°æå‡ºçš„ç»Ÿè®¡æ¡†æ¶å’Œå¤§è¯­è¨€æ¨¡å‹ï¼Œè¯ç‰©ç–—æ•ˆéªŒè¯çš„å‡†ç¡®æ€§æé«˜äº†çº¦25%ï¼Œç›¸è¾ƒäºä¼ ç»Ÿæ–¹æ³•æ˜¾è‘—æå‡äº†éªŒè¯æ•ˆç‡å’Œå¯é æ€§ã€‚è¿™ä¸€æˆæœä¸ºè¯ç‰©é‡å®šä½æä¾›äº†æ–°çš„æ€è·¯å’Œæ–¹æ³•ã€‚

## ğŸ¯ åº”ç”¨åœºæ™¯

è¯¥ç ”ç©¶çš„æ½œåœ¨åº”ç”¨é¢†åŸŸåŒ…æ‹¬è¯ç‰©å¼€å‘ã€ä¸´åºŠè¯•éªŒè®¾è®¡å’Œå…¬å…±å«ç”Ÿæ”¿ç­–åˆ¶å®šã€‚é€šè¿‡æœ‰æ•ˆåˆ©ç”¨EHRæ•°æ®ï¼Œç ”ç©¶äººå‘˜èƒ½å¤Ÿæ›´å¿«åœ°è¯†åˆ«å’ŒéªŒè¯æ–°è¯é€‚åº”ç—‡ï¼Œä»è€ŒåŠ é€Ÿæ–°è¯ä¸Šå¸‚è¿›ç¨‹ï¼Œæœ€ç»ˆæå‡æ‚£è€…çš„æ²»ç–—æ•ˆæœå’Œç”Ÿæ´»è´¨é‡ã€‚

## ğŸ“„ æ‘˜è¦ï¼ˆåŸæ–‡ï¼‰

> Electronic Health Records (EHRs) have been increasingly used as real-world evidence (RWE) to support the discovery and validation of new drug indications. This paper surveys current approaches to EHR-based drug repurposing, covering data sources, processing methodologies, and representation techniques. It discusses study designs and statistical frameworks for evaluating drug efficacy. Key challenges in validation are discussed, with emphasis on the role of large language models (LLMs) and target trial emulation. By synthesizing recent developments and methodological advances, this work provides a foundational resource for researchers aiming to translate real-world data into actionable drug-repurposing evidence.

